UBS Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $40

Futu NewsJan 11 06:31 · Ratings

Guardant Health Holds 'Underappreciated' Catalyst Path, UBS Says

MT NewswiresJan 11 04:12

Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $45

Futu NewsJan 11 02:31 · Ratings

Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42

Futu NewsJan 8 21:31 · Ratings

Jefferies Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $42

Futu NewsJan 8 07:31 · Ratings

Express News | Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection

BreakingsJan 7 21:03